25-deacetylrifampicin: main metabolite of rifampin in biological fluids; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 135889898 |
MeSH ID | M0101133 |
Synonym |
---|
16783-99-6 |
25-deacetylrifampicin |
25-o-deacetyl-3-[(e)-[(4-methyl-1-piperazinyl)imino]methyl]rifamycin |
25-desacetylrifampin |
25-desacetyl rifampicin |
J-010398 |
Q27284245 |
Excerpt | Reference |
---|---|
" The bioavailability of the active, orally administered rifampicin decreased from 93% after the first single oral dose to 68% after 3 weeks of oral and intravenous rifampicin therapy." | ( Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Eichelbaum, M; Jensen, JC; Loos, U; Mikus, G; Musch, E; Schwabe, HK, 1985) |
"In the bioavailability studies with drugs biotransformed to biologically active metabolities only the concentrations of the parent drug (PD) are usually taken into account even when the pharmacokinetic data on the metabolite(s) (M) are available." | ( [Correlation between pharmacokinetic parameters of rifampicin and its biologically active metabolite as related to estimation of the relative bioavailability of the antibiotic]. Dombrovskiĭ, VS; Firsov, AA; Gagaeva, EV; Kadenatsi, IB; Strachunskiĭ, LS, 1996) |
"To evaluate the comparative bioavailability of antituberculosis drugs in FDC formulations and the same doses in separate formulations of antituberculosis drugs, using a simplified protocol developed by the World Health Organization (WHO)." | ( The WHO simplified study protocol in practice: investigation of combined formulations supplied by the WHO. Kaul, CL; Kaur, KJ; Panchagnula, R; Singh, I, 1999) |
Excerpt | Reference |
---|---|
" Simulation of plasma concentrations after different dosage regimens shows that a double rate of infusion--20 mg min-1 during 1 h and then 200 mg h-1--allows plasma concentrations to be quickly reached and maintained at a 20 mg L-1 level, far higher than the minimum inhibitory concentrations of most germs." | ( Pharmacokinetics of rifampicin and desacetylrifampicin in tuberculous patients after different rates of infusion. Beucler, A; Brioude, R; Houin, G; Lafaix, C; Richelet, S; Tillement, JP, 1983) |
" administration, we concur with the current dosage recommendation of 10 mg/kg twice a day by mouth." | ( Pharmacokinetics of single intravenous and single and multiple dose oral administration of rifampin in mares. Kohn, CW; Kowalski, JJ; Powers, J; Sams, R; Wallace, S, 1993) |
" More research is needed to determine well-founded dosing guidelines." | ( Pharmacokinetics of intravenous rifampicin (rifampin) in neonates. Degraeuwe, PL; Neef, C; Pullen, J; Stolk, LM; van Tiel, FH; Zimmermann, LJ, 2006) |
" We determined peak concentration ranges for each drug and acetylisoniazid/isoniazid and 25-desacetylrifampicin/rifampicin ratios by analyzing 2-h post-dose samples in patients treated with standard dosing as a first-line treatment." | ( Simultaneous determination of first-line anti-tuberculosis drugs and their major metabolic ratios by liquid chromatography/tandem mass spectrometry. Jun, SH; Kim, JQ; Lee, JH; Park, KU; Song, J; Song, SH; Yoon, Y, 2007) |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 13 (44.83) | 18.7374 |
1990's | 7 (24.14) | 18.2507 |
2000's | 4 (13.79) | 29.6817 |
2010's | 5 (17.24) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 5 (16.67%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 1 (3.33%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 24 (80.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |